Safe and accurate, a recently approved dry swab device may reduce clinic-related barriers to screening for cervical cancer.

Demand and costs for care are rising at the same time that a labor shortage threatens to worsen. How can you plan for this ...

The basic lack of transparency around health care costs has long contributed to wasteful spending and inefficient care ...

VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 ...

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve ...

Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be ...

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Q1 2025 Earnings Call Transcript May 13, 2025 Capricor Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Helmy Eltoukhy; Chairman of the Board, Co-Chief Executive Officer; Guardant Health Inc Amirali Talasaz; Co-Chief Executive Officer, Director; Guardant Health Inc Hello, everybody, and welcome to the ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, ...